Has Carl Conui, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $12,451 in general payments to Carl Conui, DPM across 329 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Carl Conui, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Carl Conui, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Carl Conui, DPM

Podiatrist · Reading, MANPI 1275541773

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,676 of the $12,451 with a category attached, or 85.7%. It is spread thinly across 33 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,377 and has fallen 51.4% since, to $2,127 in 2025. Among podiatrist clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,451in general payments, 2019–2025

Across 329 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mimedx Group, Inc.$2K
Paratek Pharmaceuticals, Inc.$2K
Amgen$2K
Organogenesis Inc.$1K
Kerecis Limited$885
Smith+Nephew$746
plus $3K from 27 others

What the payments were for

Travel & lodging$1,77514%
Food & beverage$10,67686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mimedx Group, Inc.	8	$2,385
Paratek Pharmaceuticals, Inc.	117	$2,372
Amgen(2 entities)	77	$2,138
Organogenesis Inc.	18	$1,299
Kerecis Limited	7	$885
Smith+Nephew	26	$746
Musculoskeletal Transplant Foundation Inc.	7	$388
Averitas Pharma Inc.	7	$335
Orthofix Medical, Inc.	12	$228
GRT US Holding, Inc.	7	$215
Trilliant Surgical LLC.	3	$191
Amniox Medical, Inc.	3	$178
ANI Pharmaceuticals, Inc.	7	$165
Merck	1	$125
Zimmer Biomet	3	$118
Extremity Medical	1	$100
Nevro Corp.	3	$65
AbbVie	3	$63
Medtronic	2	$59
Acumed LLC	2	$49
Scilex Pharmaceuticals Inc.	1	$44
Dynasplint Systems Inc.	1	$40
Boston Scientific	2	$40
Integra Lifesciences Corporation	1	$38
Misonix Inc	2	$31
Sebela Pharmaceuticals Inc.	1	$25
Urgo Medical North America, LLC	1	$22
Medartis Inc.	1	$21
Stryker	1	$20
Emergent Biosolutions Inc.	1	$19
Bioventus LLC	1	$17
Alfasigma USA, Inc.	1	$17
Advanced Oxygen Therapy Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,451 in reported general payments places this provider in the 90th percentile of 179 podiatrist providers in Massachusetts.

See all podiatrist providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$233,634

Medicare patients

702

Services billed

3,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.